Case Type: Mergers & Acquisitions

Talaris Therapeutics Inc. (Nasdaq: TALS), relating to its proposed merger with Tourmaline Bio, Inc. Under the terms of the agreement, TALS shareholders are expected to own approximately 21.3% of the combined company.

DICE Therapeutics, Inc. (NASDAQ: DICE), relating to its proposed sale to Eli Lilly and Co. Under the terms of the agreement, DICE shareholders are expected to receive $48.00 in cash per share they own.

Quotient Technology Inc. (NYSE: QUOT), relating to its proposed sale to Neptune Retail Solutions. Under the terms of the agreement, QUOT shareholders are expected to receive $4.00 in cash per share they own.

NexTier Oilfield Solutions Inc. (NYSE: NEX), relating to its proposed sale to Patterson-UTI Energy, Inc. Under the terms of the agreement, NEX shareholders are expected to receive 0.7520 shares of Patterson per share they own.

Desktop Metal, Inc. (NYSE: DM), relating to its proposed merger with Stratasys Ltd. Under the terms of the agreement, DM shareholders are expected to receive 0.123 ordinary shares of Stratasys per Class A common stock they own.

Bunge Limited, Inc. (NYSE: BG), relating to its proposed merger with Viterra Limited.

Wireless Telecom Group, Inc. (NYSE: WTT), relating to its proposed sale to Maury Microwave, Inc. Under the terms of the agreement, WTT shareholders are expected to receive $2.13 in cash per share they own.

Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), relating to its proposed sale to Gurnet Point Capital and Novo Holdings A/S. Under the terms of the agreement, PRTK shareholders are expected to receive $2.15 in cash per share they own and a contingent value right worth up to $0.85 per share.

Chinook Therapeutics, Inc. (NASDAQ: KDNY), relating to its proposed sale to Novartis AG. Under the terms of the agreement, KDNY shareholders are expected to receive $40.00 in cash per share they own and contingent value rights worth up to $4.00 per share.

Reunion Neuroscience Inc. (NASDAQ: REUN), relating to its proposed sale to affiliates of MPM BioImpact. Under the terms of the agreement, REUN shareholders will receive $1.12 in cash per share they own.